Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies
Arthritis & Rheumatology · 2026-07 · 78 (7) · 1393-1402
DOI: 10.1002/art.43404 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Arthritis & Rheumatology, online erschienen am 21.01.2026. Verfasst von Rachael A Gordon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Hauptthemen laut MEDLINE: B-Lymphocytes, Sjogren's Syndrome, Lymphoma, B-Cell, Marginal Zone, Autoimmunity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS.
Abstract (Originalsprache)
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we explore the expanding field of SjD endotyping as a tool to enhance patient stratification, prognostication, and clinical decision‐making. SjD endotypes driven by heightened B cell activity are linked to increased lymphoma risk. B cells play a central role in SjD pathogenesis by producing autoantibodies, presenting antigens, and releasing proinflammatory cytokines. These functions contribute not only to autoimmunity but also to lymphomatous transformation. We illustrate these concepts through the case of a patient with SjD who developed parotid mucosa‐associated lymphoid tissue lymphoma after years of recurrent glandular swelling—highlighting a common yet challenging scenario for practicing rheumatologists. Using this case as a framework, we examine the pathobiology of B cells in SjD that drive autoreactivity and lymphomagenesis. Finally, we review emerging B cell–targeted therapies that reflect a broader shift in the SjD treatment landscape from symptomatic management to targeted therapies grounded in disease immunopathology. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
- Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison.
- Department of Medicine, University of Wisconsin Carbone Comprehensive Cancer Center, Madison.
ORCID-Profile: Rachael A Gordon, Sara S McCoy
Förderung
- NIAMS NIH HHS
Zitieren
APA
Gordon, R. A., & McCoy, S. S. (2026). Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies. Arthritis & Rheumatology, 78(7), 1393-1402. https://doi.org/10.1002/art.43404
Vancouver
Gordon RA, McCoy SS. Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies. Arthritis & Rheumatology. 2026;78(7):1393-1402. doi:10.1002/art.43404
BibTeX
@article{Gordon2026,
author = {Gordon, Rachael A and McCoy, Sara S},
title = {Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {7},
pages = {1393--1402},
doi = {10.1002/art.43404}
}
EUVIMED